ArticleFrontiers in immunology2025
Multi-omics analysis and evidence of IL1R1 as a potential biomarker for diabetes-associated intervertebral disc degeneration.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comprehensive genomics and functional analyses identifyTranslational cancer research · 2026Article
- The mFrontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Low back pain (LBP), primarily driven by intervertebral disc degeneration (IDD), imposes a significant global health burden. While type 2 diabetes mellitus (T2DM) is a recognized risk factor for IDD, the shared molecular mechanisms remain incompletely characterized. Methods: This study employed integrated bioinformatics (WGCNA, machine learning - LASSO, RF, ANN) on human T2DM and IDD transcriptomic datasets, alongside scRNA-seq analysis of diabetic mouse nucleus pulposus (NP) tissue, to identify key drivers of diabetes-associated IDD. Results: Bioinformatics analysis of human data identified three diagnostic biomarkers (S100A12, IL1R1, FCGR2B) and constructed a robust ANN diagnostic model (AUCs: 0.744-0.868). IL1R1 emerged as the most significant risk factor. scRNA-seq revealed altered cellular composition in diabetic discs, notably increased proportion of granulocytes (predominantly neutrophils) and decreased proportion of nucleus pulposus (NP) cells. IL1R1 was highly expressed in specific diabetes-associated NP subpopulations and showed significant positive correlation with neutrophil infiltration. Functional enrichment linked IL1R1 to inflammation, DNA repair, and immune pathways. Furthermore, we constructed a regulatory network (STAT1/STAT6-IL1R1-miRNAs-lncRNAs) and identified icariin as a potential therapeutic candidate via molecular docking. Discussion: These findings establish IL1R1 as a pivotal molecular bridge connecting T2DM and IDD, driven by neutrophil-mediated inflammation and NP cell dysfunction, offering novel diagnostic and therapeutic avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.